1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Enfermedades Neurodegenerativas: mecanismos patogénicos

Enfermedades Neurodegenerativas: mecanismos patogénicos

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Pamplona FA, Ferreira J, Menezes de Lima O, Duarte FS, Bento AF, Forner S, Villarinho JG, Bellocchio L, Bellochio L, Wotjak CT, Lerner R, Monory K, Lutz B, Canetti C, Matias I, Calixto JB, Marsicano G, Guimarães MZ, Takahashi RN.

    Anti-inflammatory lipoxin A(4) is an endogenous allosteric enhancer of CB1 cannabinoid receptor

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA . 109(51): 21134-21139. Nº de citas: 128

    [doi:10.1073/pnas.1202906109]

  • Díaz-Alonso J, Guzmán M, Galve-Roperh I.

    Endocannabinoids via CB1 receptors act as neurogenic niche cues during cortical development

    PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES . 367(1607, SI): 3229-3241. Nº de citas: 56

    [doi:10.1098/rstb.2011.0385]

  • Díaz-Alonso J, Aguado T, Wu CS, Palazuelos J, Hofmann C, Garcez P, Guillemot F, Lu HC, Lutz B, Guzmán M, Galve-Roperh I.

    The CB1 Cannabinoid Receptor Drives Corticospinal Motor Neuron Differentiation through the Ctip2/Satb2 Transcriptional Regulation Axis

    JOURNAL OF NEUROSCIENCE . 32(47): 16651-16665. Nº de citas: 58

    [doi:10.1523/JNEUROSCI.0681-12.2012]

  • Caffarel MM, Andradas C, Pérez-Gómez E, Guzmán M, Sánchez C.

    Cannabinoids: A new hope for breast cancer therapy?

    CANCER TREATMENT REVIEWS . 38(7): 911-918. Nº de citas: 69

    [doi:10.1016/j.ctrv.2012.06.005]

  • Cardinal P, Bellocchio L, Clark S, Cannich A, Klugmann M, Lutz B, Marsicano G, Cota D.

    Hypothalamic CB1 Cannabinoid Receptors Regulate Energy Balance in Mice

    Endocrinology . 153(9): 4136-4143. Nº de citas: 84

    [doi:10.1210/en.2012-1405]

  • Velasco G, Sánchez C, Guzmán M.

    Towards the use of cannabinoids as antitumour agents

    NATURE REVIEWS CANCER . 12(6): 436-444. Nº de citas: 228

    [doi:10.1038/nrc3247]

  • Bénard G, Massa F, Puente N, Lourenço J, Bellocchio L, Soria-Gómez E, Matias I, Delamarre A, Metna-Laurent M, Cannich A, Hebert-Chatelain E, Mulle C, Ortega-Gutiérrez S, Martín-Fontecha M, Klugmann M, Guggenhuber S, Lutz B, Gertsch J, Chaouloff F, López-Rodríguez ML, Grandes P, Rossignol R, Marsicano G.

    Mitochondrial CB1 receptors regulate neuronal energy metabolism

    NATURE NEUROSCIENCE . 15(4): 558-564. Nº de citas: 316

    [doi:10.1038/nn.3053]

  • Bañez-Coronel M, Porta S, Kagerbauer B, Mateu-Huertas E, Pantano L, Ferrer I, Guzmán M, Estivill X, Martí E.

    A Pathogenic Mechanism in Huntington's Disease Involves Small CAG-Repeated RNAs with Neurotoxic Activity

    PLOS GENETICS . 8(2): . Nº de citas: 126

    [doi:10.1371/journal.pgen.1002481]

  • Palazuelos J, Ortega Z, Díaz-Alonso J, Guzmán M, Galve-Roperh I.

    CB2 Cannabinoid Receptors Promote Neural Progenitor Cell Proliferation via mTORC1 Signaling

    JOURNAL OF BIOLOGICAL CHEMISTRY . 287(2): 1198-1209. Nº de citas: 108

    [doi:10.1074/jbc.M111.291294]

  • Lorente M, Torres S, Salazar M, Carracedo A, Hernández-Tiedra S, Rodríguez-Fornés F, García-Taboada E, Meléndez B, Mollejo M, Campos-Martín Y, Barcia JA, Guzmán M, Velasco G.

    Stimulation of ALK by the growth factor midkine renders glioma cells resistant to autophagy-mediated cell death

    Autophagy . 7(9): 1071-1073. Nº de citas: 20

    [doi:10.4161/auto.7.9.15866]

  • Fernández-Ruiz J, Moreno-Martet M, Rodríguez-Cueto C, Palomo-Garo C, Gómez-Cañas M, Valdeolivas S, Guaza C, Romero J, Guzmán M, Mechoulam R, Ramos JA.

    Prospects for cannabinoid therapies in basal ganglia disorders

    BRITISH JOURNAL OF PHARMACOLOGY . 163(7, SI): 1365-1378. Nº de citas: 80

    [doi:10.1111/j.1476-5381.2011.01365.x]

  • Vara D, Salazar M, Olea-Herrero N, Guzmán M, Velasco G, Díaz-Laviada I.

    Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy

    CELL DEATH AND DIFFERENTIATION . 18(7): 1099-1111. Nº de citas: 187

    [doi:10.1038/cdd.2011.32]

  • Lorente M, Torres S, Salazar M, Carracedo A, Hernández-Tiedra S, Rodríguez-Fornés F, García-Taboada E, Meléndez B, Mollejo M, Campos-Martín Y, Lakatosh SA, Barcia J, Guzmán M, Velasco G.

    Stimulation of the midkine/ALK axis renders glioma cells resistant to cannabinoid antitumoral action

    CELL DEATH AND DIFFERENTIATION . 18(6): 959-973. Nº de citas: 62

    [doi:10.1038/cdd.2010.170]

  • Andradas C, Caffarel MM, Pérez-Gómez E, Salazar M, Lorente M, Velasco G, Guzmán M, Sánchez C.

    The orphan G protein-coupled receptor GPR55 promotes cancer cell proliferation via ERK

    Oncogene . 30(2): 245-252. Nº de citas: 134

    [doi:10.1038/onc.2010.402]

  • Salazar M, Hernández-Tiedra S, Torres S, Lorente M, Guzmán M, Velasco G.

    DETECTING AUTOPHAGY IN RESPONSE TO ER STRESS SIGNALS IN CANCER

    METHOD ENZYMOL . 489: 297-317. Nº de citas: 22

    [doi:10.1016/B978-0-12-385116-1.00017-0]

  • Torres S, Lorente M, Rodríguez-Fornés F, Hernández-Tiedra S, Salazar M, García-Taboada E, Barcia J, Guzmán M, Velasco G.

    A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma

    MOLECULAR CANCER THERAPEUTICS . 10(1): 90-103. Nº de citas: 173

    [doi:10.1158/1535-7163.MCT-10-0688]

  • Blázquez C, Chiarlone A, Sagredo O, Aguado T, Pazos MR, Resel E, Palazuelos J, Julien B, Salazar M, Börner C, Benito C, Carrasco C, Diez-Zaera M, Paoletti P, Díaz-Hernández M, Ruiz C, Sendtner M, Lucas JJ, de Yébenes JG, Marsicano G, Monory K, Lutz B, Romero J, Alberch J, Ginés S, Kraus J, Fernández-Ruiz J, Galve-Roperh I, Guzmán M.

    Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease

    Brain . 134(1): 119-136. Nº de citas: 135

    [doi:10.1093/brain/awq278]

  • Caffarel MM, Andradas C, Mira E, Pérez-Gómez E, Cerutti C, Moreno-Bueno G, Flores JM, García-Real I, Palacios J, Mañes S, Guzmán M, Sánchez C.

    Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition

    MOLECULAR CANCER . 9: 196-196. Nº de citas: 105

    [doi:10.1186/1476-4598-9-196]